Pinz Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Pinz Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-475	Closed	-$564K	–	232
2022 Q1	$564K	Hold	475	–	–	0.35%	83
2021 Q4	$559K	Buy	+475	New	+$560K	0.22%	128

Other funds holding CLDI

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Pinz Capital Management's CLDI Position: Q2 2022 in Review

Pinz Capital Management sold out of Calidi Biotherapeutics (CLDI) in Q2 2022, closing a stake of 475 shares — an estimated $564K sold.

Pinz Capital Management first reported a position in CLDI in Q4 2021 and held it in 2 quarters. The position peaked at $564K in Q1 2022. 42 funds tracked by Wall St. Rank hold CLDI as of Q2 2022.

Pinz Capital Management reported no remaining Calidi Biotherapeutics position as of Q2 2022 after selling out during the quarter.
Pinz Capital Management sold 475 Calidi Biotherapeutics shares in Q2 2022, an estimated $564K.
Pinz Capital Management first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 2 quarters.
Pinz Capital Management's Calidi Biotherapeutics position peaked at $564K in Q1 2022.
42 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2022.

Based on Pinz Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.